Introduction {#sec1-1}
============

The ketogenic diet (KD) is described as a high-fat, adequate-protein, and low-carbohydrate diet. With the inadequate availability of carbohydrates, the body burns fats rather than carbohydrates to provide energy. The liver converts fat into fatty acids and produces ketone bodies (KB), which replace glucose as a primary energy source. This dietary accumulation of ketones in blood is also known as nutritional ketosis (NK).\[[@ref1]\]

Since the introduction of KD in 1920, research has emerged to understand its mechanisms and uses in various clinical conditions. Because of its pleiotropic effects on central nervous system, cellular metabolism and metabolic pathways, KD has been studied and has shown promising results in variety of neurological disorders, traumatic brain injury, acne, cancers, and metabolic disorders \[[Table 1](#T1){ref-type="table"}\].\[[@ref2][@ref3][@ref4][@ref5][@ref6][@ref7]\] Recently, ketones have been proposed as super-metabolic fuel because of their various favorable impacts on cellular metabolism in many tissues.

###### 

Clinical use of the ketogenic diet in various disorders

  -------------------------------------------
  *Endocrine disorders*
  Diabetes
  Obesity
  Metabolic syndrome
  PCOS
  Congenital hyperinsulinism
  Nonalcoholic fatty liver disease
  *Neurological disorders*
  Intractable epilepsy
  Lennox-Gastaut syndrome
  Myoclonic-astatic epilepsy
  Parkinson\'s disease
  Alzheimer\'s disease
  Amyotrophic lateral sclerosis
  Migraine/headache
  Narcolepsy
  Depression
  Autism
  *Metabolic disorders*
  Glucose transporter type 1 deficiency
  Pyruvate dehydrogenase complex deficiency
  Phosphofructokinase deficiency
  *Others*
  Trauma and ischemia
  Cancer/malignancy
  -------------------------------------------

PCOS=Polycystic ovary syndrome

This review is an attempt to summarize the evidence of KD in diabetes, obesity, and other endocrine disorders. We have also focused on application of KD in clinical practice, its benefits, as well as the cautions and contraindications to its use.

Physiology of Ketogenic Diet {#sec1-2}
============================

Glucose and fatty acids are metabolized to acetyl coenzyme A (CoA) (a product of incomplete breakdown of free fatty acids \[FFAs\] in the liver) to enter the citric acid cycle (tricarboxylic acid cycle) by condensing with oxaloacetate (pyruvate being precursor). As glycolysis falls to very low levels with KD because of low carbohydrates, oxaloacetate is not available to condense with acetyl-CoA produced by fatty acid metabolism. This leads to shunting of acetyl CoA to ketogenesis and results in accumulation of ketones.\[[@ref8]\] KB synthesized in the body are β-hydroxybutyrate (βOHB), acetoacetate, and acetone, which can also cross the blood--brain barrier to provide an alternative source of energy for the brain. Heart, muscle, and renal cortex can easily utilize KB while brain utilizes ketones only in prolonged starvation. Erythrocytes do not utilize ketones as they do not have mitochondria. Liver does not utilize ketones as it does not have the enzyme thiophorase.\[[@ref9]\]

Ketone build-up in a particular individual depends on several physiological parameters such as body fat percentage, body mass index (BMI), and resting metabolic rate.\[[@ref1]\] The KD should ideally be administered under controlled environment. KD is quite safe as the concentration of ketones in persons on KD is far lower than the concentration seen in diabetic ketoacidosis and is not associated with any changes in blood pH. It must be mentioned here that human nutrition begins with a KD: Colostrum is ketogenic and serves the needs of the neonate completely.\[[@ref10]\]

It is proposed that such diet may favor more fat loss with preservation of lean body mass. This effect is partly mediated by reduced plasma insulin levels.\[[@ref11][@ref12]\] Risk of lean body mass loss and sarcopenia can prevented with judicious supplementation of amino acids and whey protein.\[[@ref13][@ref14]\] Studies have shown induction of fibroblast growth factor-1 (FGF-1) gene by KD. FGF-1 acts as a metabolic regulator of lipolysis, serum phosphate, active Vitamin D level, and triglyceride clearance in the liver.\[[@ref15][@ref16]\]

Beneficial Impacts of Ketogenic Diet {#sec1-3}
====================================

KB as "super-fuel" efficiently produce more adenosine triphosphate (ATP) energy than glucose or fatty acids by reducing the mitochondrial nicotinamide adenine dinucleotide couple and oxidizing the coenzyme Q couple. 100 g of acetoacetate is able to generate 9.4 kg ATP and 100 g of 3-hydroxybutyrate yields 10.5 kg ATP while 100 g glucose produces only 8.7 kg ATP. This allows the body to maintain efficient fuel production in the face of calorie loss.\[[@ref10]\] KB also decreases free radical damage and enhances antioxidant capacity by activation of NF E2-related factor 2, which upregulates transcription of genes involved in protection against oxidative damage.

Impact on central nervous system {#sec2-1}
--------------------------------

There are studies supporting possible therapeutic utilization of KD in multiple neurological disorders. Potential mechanism could be neuroprotective effect by modulation in cellular energy utilization. NK has shown to improve physical and cognitive performance, improve cerebral function, and prolong survival in anoxic rats and mice. It also improves posttraumatic metabolism in man.\[[@ref17]\] KD is considered an established part of an integrative approach, along with drug therapy, in major epilepsy centers worldwide. The bioenergetic transition from glucose to KB can metabolically target brain tumors through integrated anti-inflammatory pathways/mechanisms. Enhanced phagocytic activities of macrophages, antiangiogenic, and pro-apoptotic mechanisms reduce tumor energy metabolism and glycolytic energy required for tumor growth.\[[@ref18]\]

Impact on heart {#sec2-2}
---------------

The cardiac muscle is an "omnivore," which uses diverse substrates as sources of fuel, preferring FFAs, followed by glucose, KB, lactate, pyruvate, glycogen, and amino acids. NK results in shift of myocardial fuel metabolism from fat/glucose oxidation to more energy-efficient fuel KB and improves myocardial work efficiency and function.\[[@ref10]\] The failing heart facilitates fuel metabolic shift to KB for oxidative ATP production triggered by reduced capacity for oxidizing fatty acids (the chief fuel for the normal adult mammalian heart). It attenuates free radical induced injury, improves energy reserves of the heart, increases the acetyl-CoA content of the myocardium, and improves the transduction of oxygen consumption into work efficiency at the mitochondrial level in the endangered myocardium and thereby enhancing myocardial metabolism.\[[@ref19][@ref20]\] Studies have shown that it prevents ischemic tissue damage in animal models undergoing either myocardial infarctions or stroke, leading to dramatically smaller ischemic/necrotic lesion area.\[[@ref21][@ref22]\] Electron microscopic studies show an increase in the number of mitochondria, tolerance to ischemia, and a faster recovery of cardiac function following reperfusion in rats fed with KD; hence, it is cardioprotective.\[[@ref23]\]

Impact on respiratory system {#sec2-3}
----------------------------

KD decreases the need for glucose synthesis in liver and spares its precursor, muscle-derived amino acids, and diminishes apoptosis in lung cells in shocked rodents. It decreases the death of lung cells induced by hemorrhagic shock. Moreover, it is beneficial in respiratory problems with limited oxygen supply or substrate utilization.\[[@ref17]\] It may decrease respiratory exchange ratio, carbon dioxide output, and carbon dioxide end-tidal partial pressure which proves beneficial for patients with increased arterial carbon dioxide partial pressure due to respiratory insufficiency or failure.\[[@ref24]\]

Use of Ketogenic Diet {#sec1-4}
=====================

This section describes patient selection, pre-KD counseling and evaluation, implementation of KD, supplementation, follow-up/monitoring, and eventual KD discontinuation.

Patient selection and preketogenic diet assessment {#sec2-4}
--------------------------------------------------

The pre-KD assessment requires detailed history and physical examination, specific laboratory tests, nutritional assessment, and counseling of the patient and family members. Some patients with specific metabolic disorders may have absolute contraindications to start KD. In addition, complicating risk factors (renal stones, severe dyslipidemia, significant liver disease, failure to thrive, severe gastroesophageal reflux, poor oral intake, cardiomyopathy, and chronic metabolic acidosis) may prevent initiation of KD.\[[@ref25]\]

Lot of therapeutic medications including many anticonvulsants may have high carbohydrate content and should be switched to lower carbohydrate preparations if option is available. Patients should be started on multivitamins containing adequate doses of essential minerals as well as calcium supplements before initiation of KD.\[[@ref26]\]

Application {#sec2-5}
-----------

The planning of KD requires diet instructions to lower the intake of carbohydrates to \<20 g/day, increase the intake of fats/oils, and include nutritional supplements to maintain the calorie requirement of the individual. The total amount of calories to be provided for a particular individual is based on anthropometric measurements, prior dietary intake, and physical activity. The various menu options are discussed in [Table 2](#T2){ref-type="table"}. The diet should be modified if the patient has poor dietary tolerability and frequent gastrointestinal symptoms.\[[@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32]\]

###### 

Sample menu options for ketogenic diet

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vegetarian menu                                                                                        Nonvegetarian menu
  ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------
  Breakfast                                                                                              Breakfast

   Cheese/paneer pakora\                                                                                  Scrambled whole eggs/hard boiled eggs with mozzarella and salami slices\
   Bullet coffee (coffee/tea mixed with coconut oil, cream and butter)/coffee with cream/coconut milk\    Bacon wrapped meatloaf\
   Grilled mushrooms with buttered vegetables scrambled tofu\                                             Chicken wings with cheesy cauliflower puree\
   Coconut milk or almond milk                                                                            Ham and cheese omellete\
                                                                                                          Coconut milk or almond milk

  Mid-morning                                                                                            Mid-morning

   Mushroom and onion frittata\                                                                           Pork rinds or chicken cracklings\
   Cabbage rolls with coconut\                                                                            Hamburger patties with mushroom cream sauce and bacon\
   Apple crumb pie with walnut crust cream of tomato soup with stir fried broccoli and cheesy crackers    Roast chicken (with the skin left on) and parmesan cream sauce\
                                                                                                          Roast pork belly with cauliflower cheese\
                                                                                                          Smoked salmon and cream cheese roll-ups

  Lunch                                                                                                  Lunch

   Spinach pancakes made with flaxseed flour and lots of cheese\                                          Meat pie\
   Cauliflower curry in coconut milk and coconut oil\                                                     Chicken with herb butter chicken and hummus lettuce wraps\
   Soya nugget curry\                                                                                     Baked fish with butter sauce\
   Chilli beans with sour cream, cheese and salsa\                                                        Cauliflower, chopped and sauteed in flaxeed or olive oil\
   Tofu puddings with full-fat yoghurt\                                                                   Bacon with sugar-free sausage\
   Simple salad stir fried in butter topped with lots of cheese\                                          Tuna salad lettuce leaves\
   Red channa salad with olive oil dressing                                                               Green salad with egg mayonnaise

  Evening                                                                                                Evening

   Vegetable spring rolls wrapped in lettuce with peanut sauce\                                           Hamburger patties with creamy tomato sauce\
   Pumpkin smoothie with coconut milk\                                                                    Cheese burger\
   Carrot and cucumber sticks with peanut butter\                                                         Poached eggs with spinach and melted cheese\
   Cheesy muffins topped with strawberries and blueberries\                                               Deep fried chicken wings on a bed of lettuce\
   Green tea/lemon water (without sugar)\                                                                 Chocolate chip cookie dough\
   Stir fried peanuts                                                                                     Chicken broth\
                                                                                                          Herbal tea or coffee with heavy cream without sweetener

  Dinner                                                                                                 Dinner

   Almond flour and chia seeds pancakes\                                                                  Baked salmon with lemon and butter\
   Baked tofu with cheese and cream\                                                                      Garlic chicken sprinkled with cheddar cheese chicken on salad greens with oil and vinegar\
   Fried paneer pakora\                                                                                   Ham and cheese rolled pancakes with cream mayonnaise\
   Stir fried french beans with cheese topping\                                                           Salad greens sprinkled dressed with a tablespoon of full fat dressing and cheese\
   Cream of mushroom with ghia kofta\                                                                     Shredded cabbage sauted in sesame oil
   Stir fried lady finger with peanuts (Maharashtrian style)\                                            
   Spinach cooked in milk, cream, and cheese\                                                            
   Stir fried veggies with spices and cream dressing\                                                    
   Cheesy cauliflower curry                                                                              

  Dessert                                                                                                Dessert

   Apple and zucchini cake\                                                                               Chocolate mousse or chocolate truffles\
   Poached pears topped with cocoa butters\                                                               Egg muffin cups
   Soya cheesecake\                                                                                      
   Chocolate silk pie with almond crust                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The diet is typically planned to provide 80%-90% of the energy from fat in a ratio of grams of fat to grams of protein plus carbohydrate as ''4:1'' i.e 4 g of fat to 1 g of protein plus carbohydrate. (For example=A 1500 Kcal diet can comprise 133.5 g fat with 55 g protein + 20 g carbohydrate)

KD involves flexibility to use long-chain triglycerides (LCT) or medium chain triglycerides (MCT). Omega-3 supplementation has its own positive effects.\[[@ref33]\] Fat rich diet is prescribed with low-carbohydrate fruits and vegetables in each meal. Home-based diets (with the addition of a liquid fat source, and micronutrients supplementation) as well as commercial formulas (KetoCal, Ross Carbohydrate FreeSoy Formula Base with Iron) may be used.\[[@ref25][@ref26]\]

Fluid restriction is not required and also individuals may be motivated to continue routine exercises. The carbohydrate-free or minimal carbohydrate-containing multivitamins and multimineral preparations should be administered to prevent nutritional deficiencies. Nutrients significantly required with KD are calcium with Vitamin D, selenium, magnesium, zinc, and phosphorus.\[[@ref29]\] Evaluation of the diet should be done periodically to monitor the beneficial effects and associated risks.

Monitoring urine ketones is necessary to ensure that the diet is being managed correctly. It is generally advisable that patients on KD should monitor their serum glucose, albumin, total protein, total cholesterol, triglycerides, and serum creatinine once in every 3 months. Once a year, renal ultrasound, bone density, carnitine, selenium levels, and electrocardiogram are significant with regard to the prevention of long-term effects such as nephrolithiasis, osteoporosis, hyperlipidemia, carnitine deficiency, and cardiomyopathy.

Although very low carbohydrate KD was proved to be safe and effective in morbidly obese patients scheduled for laparoscopic bariatric surgery, there is a scarcity of data on KDs being used for prebariatric surgery management of morbid obesity. Most research support the use of restricted energy diets for preoperative weight loss evidenced to reduce the risk of postoperative complications, reduce liver volume, and fat content in obese patients to improve patient outcome.

Postketogenic diet assessment {#sec2-6}
-----------------------------

The diet can be discontinued abruptly in an emergency but is more often tapered slowly over 2--3 months by gradually lowering the ketogenic ratio from 4:1--3:1--2:1. Calories and fluids are increased *ad libitum*, and larger amounts of carbohydrate foods and nutritional supplements are reintroduced with loss of urinary ketones.\[[@ref25]\]

Evidence of Ketogenic Diet in Endocrine Disorders {#sec1-5}
=================================================

The favorable effects of KD on caloric intake, body weight, lipid parameters, glycemic indices, and insulin sensitivity render it a therapeutic option in metabolic syndrome, obesity, and obese type 2 diabetes. Various hormones such as insulin, glucagon, cortisol, catecholamines, and growth hormone also significantly affect ketone-body metabolism.\[[@ref34]\]

Diabetes {#sec2-7}
--------

A variety of dietary modifications has been studied to improve glycemic control such as low calorie diet, low-fat diet, low-protein diet, high-protein diet, and low glycemic load diet.\[[@ref35]\] Since the dietary carbohydrate is the major macronutrient that raises the blood glucose levels, researchers have aimed to reduce the amount of carbohydrate in the meals to study the effects on glycemic load, antidiabetic regimen, and drug dosage among diabetic people. Dietary carbohydrate restriction reliably reduces high blood glucose, does not require weight loss (although is still best for weight loss), and leads to the reduction or elimination of medication.\[[@ref28][@ref36]\] Studies of KD looking into benefit on glycemic indices and other metabolic parameters in patients with type 2 diabetes are summarized in [Table 3](#T3){ref-type="table"}.\[[@ref28][@ref37][@ref38][@ref39][@ref40]\]

###### 

Studies of ketogenic diet in type 2 diabetes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year and site of the study                    Sample description                                                 Intervention and duration                                                                                              Study parameters                                                                                    Results
  --------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Westman *et al*. 2008 USA                     84 obese and type 2 diabetic community volunteers\                 Randomly assigned LCKD and LGID Nutritional supplements and exercise recommended 24 weeks 49 (58.3%) completed study   HbA1c, fasting glucose, fasting insulin, weight loss, cholesterol                                   HbA1c, fasting glucose, fasting insulin, weight loss improved in both groups\
                                                18-65 years with BMI: 27-50 kg/m^2^                                                                                                                                                                                                                                                           Significantly greater improvement among LCKD group in\
                                                                                                                                                                                                                                                                                                                                              HbA1c (*P*=0.03)\
                                                                                                                                                                                                                                                                                                                                              Body weight (*P*=0.008)\
                                                                                                                                                                                                                                                                                                                                              HDL cholesterol (*P*\<0.001)\
                                                                                                                                                                                                                                                                                                                                              Reduced anti-diabetic drugs to 95.2% in LCKD group versus 62% in LGID group (*P*\<0.01)

  Dashti *et al*. 2007                          64 healthy obese diabetic subjects                                 Study parameters determined before and at 8, 16, 24, 48 and 58 weeks after KD being administered                       Body weight, BMI, blood glucose level, total cholesterol, LDL-cholesterol, triglycerides and urea   Significant reduction in body weight, BMI, blood glucose level, total cholesterol, LDL-cholesterol, triglycerides and urea from week 1-56 (*P*\<0.0001)\
                                                                                                                                                                                                                                                                                                                                              HDL-cholesterol increased significantly (*P*\<0.0001)\
                                                                                                                                                                                                                                                                                                                                              More significant results in subjects with hyperglycemia

  Boden *et al*. 2005 University hospital       10 obese patients with type 2 DM                                   Inpatient comparison of 2 diets\                                                                                       Weight loss, 24-h blood glucose profiles, insulin sensitivity\                                      KD resulted in significant\
                                                                                                                   Usual diets for 7 days followed by KD for 14 days                                                                      HbA1c, triglyceride and cholesterol levels                                                          Spontaneous reduction in energy intake\
                                                                                                                                                                                                                                                                                                                                              Weight loss Improved 24-h blood glucose profiles, insulin sensitivity, and HbA1c Decreased plasma triglyceride and cholesterol levels

  Yancy *et al*. 2005 Durham VAMC clinic, USA   21 type 2 diabetic overweight participants 3 white, 8\             LCKD counseling Medication adjustment 16 weeks                                                                         HbA1c, fasting serum triglyceride, drug dosage and waist measurement                                HbA1c decreased by 16%\
                                                African-American Mean±SD age 56.0±7.9 years BMI 42.2±5.8 kg/m^2^                                                                                                                                                                                                                              Mean body weight decreased by 6.6%\
                                                                                                                                                                                                                                                                                                                                              Fasting serum triglyceride decreased 42%\
                                                                                                                                                                                                                                                                                                                                              Reduction in antihyperglycemic medications\
                                                                                                                                                                                                                                                                                                                                              Positive effect on waist measurement

  Gumbiner *et al*. 1996                        13 obese patients with type 2 diabetes                             7 patients treated with high-ketogenic VLED for 3 weeks\                                                               Fasting and OGTT plasma insulin, C-peptide concentrations and HGO                                   Fasting and OGTT glycemia were lower during treatment with high-ketogenic VLED (*P*\<0.05) Strong correlation between basal HGO and fasting plasma ketone bodies (*P*\<0.05)\
                                                                                                                   6 patients treated with low-ketogenic VLED for 3 weeks\                                                                                                                                                                    No significant difference in weight loss, fasting and OGTT plasma insulin and C-peptide concentrations
                                                                                                                   Patients crossed over and treated with alternate diet for another 3 weeks                                                                                                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

VLED=Very low-energy diets, HGO=Hepatic glucose output, LCKD=Low carbohydrate ketogenic diet, KD=Ketogenic diet, LGID=Low-glycemic, reduced calorie diet, HDL=High-density lipoprotein, OGTT=Oral glucose tolerance test, VAMC=Veterans Affairs Medical Center, BMI=Body mass index, SD=Standard deviation, DM=Diabetes mellitus, LDL=Low-density lipoprotein, HbA1c=Glycosylated hemoglobin

The analysis of the KD map from the diabetes perspective identifies strong relationship between the insulin resistance pathway and KD. It highlights that elements of lipid metabolism may facilitate proper cellular localization of glucose transporters, recycling, and KB can alleviate certain inflammatory processes by blocking specific cytokines.\[[@ref28][@ref36]\] With the increased plasma ketones, there is decreased plasma glucose, decreased cerebral metabolic rate of glucose (CMRglc), and increased cerebral metabolic rate of acetoacetate (CMRa).\[[@ref41]\] In obese patients with type 2 DM, high-ketogenic VLED treatment lowers fasting, OGTT glycemia, and improves glycemic control.\[[@ref40][@ref42]\] High-protein, low-carbohydrate KD reduces hunger, and lowers food intake.\[[@ref43]\] KD are significantly beneficial in improve glycemic control (glycated hemoglobin), eliminate/reduce diabetic medications, increase high-density lipoprotein-cholesterol (HDL-C), and cause weight loss in overweight and obese individuals with type 2 diabetes over a 24-week period compared to low glycemic index diet.\[[@ref39][@ref44]\] Moreover, limiting both protein and carbohydrates in KD reverses diabetic nephropathy.\[[@ref45]\] However, such diet may not benefit in preventing the decline in β-cell function and may not improve the insulin secretory function or β-cell mass.\[[@ref46]\]

Sodium glucose cotransporter 2 (SGLT2) inhibitors, especially empagliflozin and canagliflozin, has been shown to have cardiovascular benefits in patients with type 2 diabetes. SGLT 2 inhibitors also exhibit pro-ketogenic effects by mediating a metabolic switch from glucose to lipid utilization. As a class they increase the production of KB in the liver, by increasing glucagon levels and reducing the insulin: glucagon ratio. One of the postulated mechanisms behind their exceptional cardiovascular and renal benefits in patients with type 2 diabetes is likely because of mild ketosis with these drugs, resulting in improvement of peripheral insulin sensitivity, reducing hyperinsulinemic stress, and inherent insulin secretion with lowered requirement for external insulin. Mild ketosis also has beneficial effects on the myocardial metabolism, for the failing diabetic heart. However, patients with type 2 diabetes who are already receiving SGLT2 inhibitors, have significantly higher risk of developing euglycemic diabetic ketoacidosis if put on low carbohydrate KD; hence, KD should not be prescribed to patients with type 2 diabetes on SGLT2 inhibitors.\[[@ref10]\]

Among patients with diabetes, carbohydrate restriction may increase the risk of hypoglycemia, especially in patients treated with insulin and insulin secretagogues (sulfonylureas, incretin-based therapies). Hence, modification in drug dosage is recommended before initiating such diet depending on glycemic control and class of antidiabetes medication therapy.\[[@ref47]\]

Obesity {#sec2-8}
-------

In obese patients, KD treatment had shown greater weight loss as compared to other balanced diets. This comparative greater weight loss makes it an alternative tool against obesity.\[[@ref48][@ref49][@ref50]\] The possible mechanisms for higher weight loss may be controlled hunger due to higher satiety effect of proteins, direct appetite suppressant action of KB, and changes in circulating the level of several hormones such as ghrelin and leptin which controls appetite.\[[@ref51][@ref52]\] Other mechanisms proposed are reduced lipogenesis, increased lipolysis, reduction in resting respiratory quotient, increased metabolic costs of gluconeogenesis, and the thermic effect of proteins.\[[@ref53][@ref54]\]

A study conducted by Castaldo *et al*. in 2016 shows that short-term ketogenic EN followed by an almost carbohydrate-free oral nutrition may effectively reduce body weight, waist circumference, blood pressure, and insulin resistance in clinically healthy morbidly obese adults (BMI ≥45 kg/m^2^).\[[@ref55]\] The diet significantly decreases cholesterol, blood glucose, body weight, BMI, and thereby reducing risk factors for various chronic diseases among obese hypercholesterolemic patients (BMI \>35 kg/m^2^) without any side effects in long term.\[[@ref56]\]

Metabolic syndrome {#sec2-9}
------------------

Insulin resistance in peripheral tissues manifests as hyperglycemia, hyperinsulinemia, abnormal fatty acid metabolism and atherogenic dyslipidemia in MetS, and cardiovascular diseases. Dietary carbohydrate modulates lipolysis, assembly, and processing of lipoprotein.\[[@ref47][@ref57]\] KD in long term (12 months or more) results in decreased body weight, triglycerides, and diastolic blood pressure whereas it causes increased HDL-C and low-density lipoprotein-C as compared to low fat diet.\[[@ref53][@ref58]\]

The elevated plasma βOHB correlates with decreased plasma cholesterol, mevalonate (a liver cholesterol synthesis biomarker) and lower levels of the mevalonate precursors acetoacetyl-CoA and 3-hydroxy-3-methylglutaryl-CoA in liver. Increased βOHB promotes a nonatherogenic lipid profile, improves cardiovascular risk parameters, lowers blood pressure, diminishes resistance to insulin, without any adverse impact on renal or liver functions.\[[@ref59][@ref60]\]

Polycystic ovary syndrome {#sec2-10}
-------------------------

Polycystic ovary syndrome (PCOS) is associated with obesity, hyperinsulinemia, insulin resistance, reproductive and metabolic implications. The metabolic and endocrine effects of low carbohydrate KD are evidenced by improvements in body weight, free testosterone percentage, luteinizing hormone/follicle-stimulating hormone ratio, and fasting insulin levels. It leads to decrease in androgen secretion and increase in sex-hormone binding globulin, improves insulin sensitivity and thereby renormalizes endocrine functions. Such dietary intervention and lifestyle management has beneficial effects in the treatment of PCOS patients affected with obesity and type 2 diabetes.\[[@ref61][@ref62][@ref63]\] It has also been shown to improve depressive symptoms, psychological disturbances, and health-related quality of life in these patients.\[[@ref64]\]

The detailed discussion of KD in nonendocrine disorders is outside the scope of this review. The possible disease specific modifying effects of KD in nonendocrine disorders are summarized in [Table 4](#T4){ref-type="table"}.\[[@ref3][@ref65][@ref66][@ref67][@ref68][@ref69][@ref70][@ref71]\]

###### 

Disease specific modifying effects of ketogenic diet in nonendocrine disorders

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease condition                Beneficial effects
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Metabolic conditions             Beneficial effects in GLUT1 deficiency syndrome and PDHC deficiency\
                                   Improved exercise tolerance and decreased baseline creatinine kinase levels in McArdle disease\
                                   Provides energy substrates in glycolysis for the conversion of fructose-6-phosphate to fructose-1,\
                                   6-bisphosphate during PFK deficiency\
                                   Improved muscle strength and developmental milestones among patients with mutations in the muscle isoform of PFK, myopathy and arthrogryposis

  Epilepsy                         Provides alternative substrates for CNS and TCA cycle\
                                   Enhanced mitochondrial function and GABA synthesis in brain\
                                   Ketone metabolism generates protons and pH-lowering metabolic products, associated with its anticonvulsant activity\
                                   Increased levels of acetone might activate K2P channels to hyperpolarize neurons and limit neuronal excitability\
                                   Stabilizes neuronal membrane potential, produces change in neuromodulators, modifies neural circuits and normalizes neuronal function\
                                   Inhibition of glutamatergic excitatory synaptic transmission improvements in infantile spasms\
                                   Management of tuberous sclerosis complex with the improved seizure control

  Neurodegenerative disorders\     May regulate a family of proteins (sirtuins), which play a major role in mediating "anti-aging" effects of calorie restriction\
   Parkinson\'s disease\           May regulate a master energy-sensing protein in the cell, 5'-AMP-activated kinase having downstream effectors that may possess neuroprotective properties\
   Alzheimer disease               Beneficial impact on glucose use and brain-derived neurotrophic factor\
                                   May protect against the deposition of amyloid and allow cells to overcome amyloid-induced PDH dysfunction

  Amyotrophic lateral sclerosis    Significantly more preservation of motor neurons in mice May provide substrate to bypass impaired or poorly functioning complex I\
                                   However, did not significantly prolong survival among such mice

  Migraine, headache, narcolepsy   Limited studies\
                                   Mechanism of benefit not clear

  Depression                       Similar behavioral changes as antidepressants

  Trauma                           Ketones may be a preferred fuel in the injured brain hence protective against trauma and ischemia Significant decrease in cortical contusion area in rats

  Ischemia                         Increased number of mitochondria in cardiac muscle leads to improved capacity to generate energy with cardioprotective effect in face of ischemic insult

  Cancer/malignancy                Brian tumor cells are less able than healthy brain tissue to use ketones as an energy source\
                                   May restrict glucose required to produce components critical to proliferative cell growth in tumor cells\
                                   Provide additional energy substrate to normal healthy tissues at risk of cell death
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

KD=Ketogenic diet, GLUT-1=Glucose transporter type 1, CNS=Central nervous system, PDH=Pyruvate dehydrogenase, TCA=Tricarboxylic acid, PFK=Phosphofructokinase, AMP=Adenosine monophosphate, PDHC=Pyruvate dehydrogenase complex, GABA= Gamma-aminobutyric acid

Adverse Effects {#sec1-6}
===============

Adverse effects can be classified either as mild, moderate, and severe or short term and long term \[[Table 5](#T5){ref-type="table"}\].\[[@ref72][@ref73]\] Common adverse effects are mild and include headache, constipation, diarrhea, insomnia, and backache. High level of MCTs in KD may cause gastrointestinal discomfort with reports of abdominal cramps, diarrhea, and vomiting.\[[@ref25]\] The moderate adverse effects comprised of dyslipidemia, mineral deficiencies, metabolic acidosis, and increased risk of renal stones. It may lead to increased triglycerides within a period of 6 months.\[[@ref73][@ref74]\] Hypoproteinemia is also commonly observed; which could be due to associated reduced protein intake.\[[@ref75]\] The severe effects are associated with elevated levels of ketones that can lead to complications by increasing redox imbalance and thereby risk of morbidity and mortality in diabetic patients.\[[@ref76]\] With regard to possible acidosis during KD, as the concentration of KBs never rises above 8 mmol/L, this risk is virtually nonexistent in subjects with normal insulin function.

###### 

Adverse effects of ketogenic diets

  ---------------------------------
  *Short-term effects*
  Nausea/vomiting
  Constipation
  Dehydration
  Anorexia
  Lethargy
  Hypoglycemia
  Acidosis
  *Long-term effects*
  Disruptions in lipid metabolism
  Severe hepatic steatosis
  Hypoproteinemia
  Mineral deficiencies
  Increase redox imbalance
  Cardiomyopathy
  Nephrolithiasis
  ---------------------------------

Long-term KD causes glucose intolerance associated with insufficient insulin secretion, insulin resistance, and reduced beta and alpha cell mass in mice (the long-term effects on pancreatic endocrine cells).\[[@ref77]\] There are risks of more visceral and bone marrow fat, increased leptin, decreased insulin-like growth-factor 1, reduced bone mineral density, reduced transcription factors promoting osteoblastogenesis, and hence, reduced bone formation.\[[@ref78]\] Plasma markers associated with dyslipidemia and inflammation (cholesterol, triglycerides, leptin, monocyte chemotactic protein-1, Interleukin \[IL\]-1, and IL-6) were increased, and KD-fed mice showed signs of hepatic steatosis after 22 weeks of KD.\[[@ref77]\]

Some of the adverse effects may be preventable and easily treatable such as dehydration, hypoglycemia, and mild acidosis. Less quantity of MCT combined with LCT and increased meal frequency may improve diet tolerance.\[[@ref25]\] Supplements of calcium, selenium, zinc, vitamin D, and oral alkalis are prescribed to reduce the incidence of nutritional deficiencies and kidney stones.\[[@ref66]\] H2-blockers or proton pump inhibitors may be prescribed to prevent gastrointestinal dysmotility and gastroesophageal reflux.\[[@ref25]\] In addition, high-fiber vegetables, sufficient fluids, and if necessary, carbohydrate-free laxatives are recommended to overcome constipation.

Cautions and Contraindications {#sec1-7}
==============================

The metabolic adaptation to the KD involves a shift from use of carbohydrates to lipids as the primary energy source. As such, a patient with a disorder of fat metabolism might develop a devastating catabolic crisis (i.e., coma, death) in the setting of fasting or a KD. Therefore, before initiating the KD, patients must be screened for disorders of fatty acid transport and oxidation, especially for children with seizure disorders and developmental abnormalities. KD is also contraindicated in porphyria (a disorder of heme biosynthesis in which there is deficient porphobilinogen deaminase), and patients with deficiency of pyruvate carboxylase enzyme\[[@ref25]\] \[[Table 6](#T6){ref-type="table"}\].\[[@ref10][@ref79]\] Hence, detailed history, physical examination, growth assessment in children and routine laboratory monitoring is indispensible before KD initiation and during follow-up visits. KD should not be advised for diabetic patients on SGLT2 inhibitors, as discussed in the previous section.

###### 

Cautions and contraindications of ketogenic diet

  -----------------------------------------------------------
  *Inborn errors of fat metabolism and enzyme deficiencies*
  MCAD
  LCAD
  SCAD
  Long-chain 3-hydroxyacyl-CoA deficiency
  Medium-chain 3-hydroxyacyl-CoA deficiency
  Beta-oxidation defects within the mitochondria
  Pyruvate carboxylase deficiency
  Carnitine deficiency
  CPT I or II deficiency
  Carnitinetranslocase deficiency
  Porphyria
  *Other complicating risk factors*
  Renal stones
  Severe dyslipidemia
  Significant liver disease
  Failure to thrive
  Severe gastroesophageal reflux
  Poor oral intake
  Cardiomyopathy
  Chronic metabolic acidosis
  Patients receiving SGLT 2 inhibitors
  -----------------------------------------------------------

SGLT 2=Sodium glucose co transporter 2, CPT=Carnitine palmitoyl transferase, SCAD=Short-chain acyl dehydrogenase deficiency, LCAD=Long-chain acyl dehydrogenase deficiency, MCAD=Medium-chain acyl dehydrogenase deficiency

Conclusion {#sec1-8}
==========

There is clinical evidence to support the use of KD in diabetes, obesity, and endocrine disorders. KD is gaining interest but is to be performed under strict medical supervision of dieticians and physicians to be effective and may, therefore, require hospital settings for its initiation. To facilitate the patient acceptability, tolerability, and palatability, the diet protocols are gradually modified including initiation of the diet with or without fasting, regular follow-ups to minimize complications, changes in ratios of the fat versus nonfat components and fatty acids composition. Such diets may positively influence hormonal balance and endocrinological disorders, but future studies are required to assess the long-term effects on health and reversing of diabetic complications in humans. The understanding of clinical impacts, safety, tolerability, efficacy, duration of treatment, and prognosis after discontinuation of the diet is challenging and requires further studies to understand the disease-specific mechanisms.
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